NCT06158334View on ClinicalTrials.gov

Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)

RecruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

December 1, 2024

Conditions
Hemophilia AHemophilia B
Interventions
DRUG

Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures

All surgical data will be collected: surgery, biology, administration of Elocta®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding

DRUG

Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures

All surgical data will be collected: surgery, biology, administration of Alprolix®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding…

Trial Locations (1)

Unknown

RECRUITING

Centre de Référence en Hémophilie, hôpityal Louis Pradel, GHE- Hospices Civils de Lyon, Bron

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER